New advancements/Articles
This page shows new advancements and studies for IBD.
Make sure to click on the links for more detail and visit the original sources for more accurate descriptions.
(links listed below and on image)
Make sure to click on the links for more detail and visit the original sources for more accurate descriptions.
(links listed below and on image)
Less frequent colon cancer screening may be safeBas Oldenburg, MD, and collegues wrote to justify longer surveillance intervals for low-risk patients. They defined a colonoscopy as negative if it found no polyps, strictures, or endoscopic disease activity. 44% of patients in the data base had at least one negative colonoscopy. They wrote that the longer intervals could optimize the cost and resource to benefit ratio of surveillance and improve the patients quality of life. Oldenburg said, “We identified that in a selected low-risk group, having two consecutive negative surveillance examinations predicts a very low and potentially negligible risk of aCRN on continued follow-up."
www.healio.com/gastroenterology/inflammatory-bowel-disease/news/online/%7Bf17ee15a-63e3-4fc2-8aa0-b2d2301a023d%7D/less-frequent-colon-cancer-screening-may-be-safe-in-some-ibd-patients |
Less Ulcerative Colitis patients will need their colon removed thanks to biologics
Fernando Velayos, Kaiser Permanente, found that the rate of colectomy within the first year has declined with the use of biologics. A study was conducted that only 5.3% of patients underwent colectomy during their first hospitalization, when previously it was at 20%. Now only 11.9% underwent surgery during the first year, compared to historical rates of 30%. This research shows that the natural history of colectomy may be different and modifiable in the modern era of biologics.
www.crohnscolitisfoundation.org/news/5-major-advances-ibd-treatment |
New drug in pipeline for crohn's diseaseMei Wang, Dizal Pharmaceuticals, presented the Phase I study of AZD4205. There is currently no cure for Crohn's Disease, and many drugs do not work on all patients. AZD4205 is an oral, ATP-competitive, JAK1 selective inhibitor. Nonclinical data showed its higher drug concentration in the intestines relative to plasma in the rodents. This is said to suggest that it may become an effective and safe treatment option. The drug is currently being evaluated in healthy volunteers during Phase I, and Phase II is planned.
www.crohnscolitisfoundation.org/news/5-major-advances-ibd-treatment |
Lymphoma not associated with anti-TNF therapy in pediatric IBD patientsA study conducted by Matthew D. Egberg, from the University of North Carolina, Chapel Hill, found that aTNF drugs are among the most effective medications to treat IBD in pediatrics. However, there have been concerns that they would have an association with lymphoma. Based on a diverse and large amount of insurance claims of 9,284 patients, aTNF agents were not associated with lymphomas and did not increase the level of malignancy.
www.crohnscolitisfoundation.org/news/5-major-advances-ibd-treatment aTNF- anti-tumor necrosis factor |
Connection between Ulcerative Colitis and AnemiaAnemia is a condition characterized by a deficiency of RBC. It can be common for people with Ulcerative Colitis. The article written by Ashley Welch and medically reviewed by Kareem Sassi, MD., explains the connection between the two conditions. Due to the presence of inflammation, patients absorb iron poorly. Additionally, some iron rich foods may be hard for UC patients to tolerate. Bloody stools, a common symptom, causes them to lose RBC as well. A study by BioMed Research International estimated 21% of UC patients to develop anemia.
RBC-red blood cells UC-ulcerative colitis https://www.everydayhealth.com/ulcerative-colitis/symptoms/the-colitis-anemia-connection/ |
Non-coding RNAs contribute to inflammatory bowel diseaseLihui Lin and Gaoshi Zhou are a part of the division of Gastroenterology at a Universtiy in China. Theyhave speculated and made strong connections between IBD and noncoding RNAs. ncRNAs include lngRNA and circRNA which are likely to drive personalized therapy for IBD. They also enable accurate diagnosis, prognosis, and therapeautic response. Further in the article, they talk about how these RNAs are involved in the nosogenesis of IBD and are emerging as biomarkers. IncRNAs and circRNAs are involved in the pathogenesis of IBD.
https://www.nature.com/articles/s41419-020-2657-z#citeas RNA-ribonucleic acid ncRNA- noncoding RNA IncRNA- long coding RNA circRNA- circular coding RNA IBD- Inflammatory Bowel Disease |
New drug to treat IBD available 2023Hulio, a Humira Biosimilar gets FDA approval Crohn's and Colitis. However, it is not available until 2023. In an article posted on July 13, 2020 mentions that this new medication was developed by Mylan and Fujifilm Kyowa Kirin Biologics and will be available when the Humira patent expires. The expected launch is July 2023, according to an agreement with AbbVie, Humira's developer. Hulio is said to be obtainable as prefilled syringes and auto-injecter pens. The article also says that, "The FDA's approval of Hulio also covers five additional indications: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults, and juvenile idiopathic arthritis in patients ages 4 and older. "
https://ibdnewstoday.com/2020/07/13/hulio-humira-biosimilar-ibd-gets-fda-nod-will-be-available-2023/ |
Sweetened beverages do not increase IBD riskPrevious studies have linked sweetened beverages to an increased risk of IBD. New studies show no evidence of this. Hamed Khalili, MD, began looking into the obesity epidemic and searched for an association with IBD. He said, "Since there is increasing data on the role of obesity in inflammatory bowel disease, we thought that this is an important question that’s worth examining." They began analyzing dietary lifestyles of 83,042 men and women. Their studies found no association between higher consumption of these beverages and developing Crohn's or Colitis. In the article he states, "The adjusted HRs for at least one daily serving vs. no consumption of sweetened beverages were 1.02 (95%; 0.6-1.73) for Crohn’s disease and 1.14 (95%; 0.83-1.57) for ulcerative colitis."
www.healio.com/news/gastroenterology/20180514/drinking-sweetened-beverages-does-not-appear-to-increase-ibd-risk |
Dietary patterns associated with Crohn's DiseaseIn a research study conducted, it was found that there were three dietary patterns that significantly impacted the disease. However, prospective studies are needed to determine the effects of food consumption. The patterns were:
1. traditional + FODMAP- showed higher consumptions in rice, pasta, red and poultry meat, legumes, industrialized juice, soft drink, and FODMAP. 2. fitness style- showed high loadings for tapioca, eggs, pepper, olive, canned, and fruits. 3. snacks and processed foods- consisted of higher consumption of pizza, pie, snacks, cheese, red and poultry meat, and sausages. Pattern 1 was associated with ≥5 symptoms, previous surgeries, and 1 to 5 years of the disease and negatively associated with being male. Pattern 2 "was positively associated with physical activity, in which a meta-analysis showed that it has a protective effect in CD24; whereas higher BMI and smoking were negatively associated with this pattern." Lastly, pattern 3 ) was associated with>10 years of the disease and negatively associated with older age group, between 30 and 60 years. Overall, the study did not find any association between eating patterns and different stages of the disease. https://www.nature.com/articles/s41598-020-64024-1 |